Physician profile
Song Li
NPI 1376832998
$27,362.97
in general payments reported to CMS, 2019-2025
26 companies · $6,732 in 2025
The $6,732 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2021: $158 · 2022: $928 · 2023: $1,020 · 2024: $17K · 2025: $6,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $18K · Food and Beverage: $7,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $17,860.12 |
| Food and Beverage | $7,338.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $22,249.49 | 2019-2025 | Impella |
| Abbott Laboratories | $2,775.66 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic, INC. | $337.35 | 2021-2022 | |
| Medtronic Vascular, INC. | $289.42 | 2019 | |
| Atricure, INC. | $242.85 | 2024-2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Epi-Ease Epicardial Access System |
| Alnylam Pharmaceuticals INC. | $225.52 | 2024-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $165.80 | 2025 | Inspiris Resilia Aortic Valve |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $136.33 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $129.23 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $125.69 | 2024-2025 | |
| Novo Nordisk INC | $113.40 | 2024-2025 | Ozempic |
| Ethicon US, LLC | $47.26 | 2023-2024 | Stratafix, Dermabond Prineo |
| Analog Devices INC. | $45.33 | 2025 | Sensinel Cpm Wearable |
| Kestra Medical Technology Services, INC. | $41.95 | 2025 | Assure Wcd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.48 | 2024 | Farxiga |
| Baxter Healthcare | $33.23 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Invivyd INC | $32.81 | 2025 | Pemgarda |
| Daiichi Sankyo INC. | $29.39 | 2023 | Injectafer |
| Pfizer INC. | $27.14 | 2024 | |
| Bridgebio Pharma, INC. | $26.43 | 2025 | Attruby |
| Takeda Pharmaceuticals U.S.A., INC. | $24.37 | 2023 | Livtencity |
| Merck Sharp & Dohme LLC | $17.97 | 2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.87 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.55 | 2025 | Lifevest |
| Exact Sciences Corporation | $15.41 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Song Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.